Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program

Journal of General Internal Medicine

Volumn 30, Issue 7, 2015, Pages 950-957

  Trooskin, Stacey B ^a   Poceta, Joanna ^b,d   Towey, Caitlin M ^c,d   Yolken, Annajane ^c,d   Rose, Jennifer S ^e   Luqman, Najia L ^d   Preston, Ta Wanda L ^d   Chan, Philip A ^b,f   Beckwith, Curt ^b,f   Feller, Sophie C ^g   Lee, Hwajin ^c,d   Nunn, Amy S ^c,d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b MIRIAM HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d RHODE ISLAND PUBLIC HEALTH INSTITUTE   (United States)

^e WESLEYAN UNIVERSITY   (United States)

^f BROWN UNIVERSITY   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

community based screening; continuum of care; HCV screening; hepatitis C; patient navigation

Indexed keywords

HEPATITIS C VACCINE; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENERAL PRACTITIONER; GEOGRAPHY; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICALLY UNDERSERVED; MIDDLE AGED; PATIENT CARE; PATIENT REFERRAL; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; SCREENING TEST; SEROPREVALENCE; UNITED STATES; CASE MANAGEMENT; COMMUNITY CARE; HEALTH CARE PLANNING; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; HIGH RISK BEHAVIOR; MASS SCREENING; ORGANIZATION AND MANAGEMENT; PENNSYLVANIA; PRIMARY HEALTH CARE; PROCEDURES; PROGRAM EVALUATION; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CASE MANAGEMENT; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH; MALE; MASS SCREENING; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; PATIENT NAVIGATION; PENNSYLVANIA; PRIMARY HEALTH CARE; PROGRAM EVALUATION; REFERRAL AND CONSULTATION; RISK-TAKING; SOCIOECONOMIC FACTORS;

EID: 84931560419     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3209-6     Document Type: Article

References (52)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090–101. Epub 2011 Mar 15.
3. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate [Abstract #44]. Oral presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (Boston) 2005. Hepatology. 2005;42(4 Suppl 1):213A.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.
6. Singal AG, Volk ML, Jensen D, Di Bisceqlie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8. Epub 2009 Nov 27.
7. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61. Epub 2012 Apr 10.
8. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. 2012;17;61(RR04):1–18.
9. Denniston MM, Jiles RB, Drobenius J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic Hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.
10. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366(3):273–5.
11. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.
12. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.
13. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clin Gastroenterol Hepatol. 2014;12(5):728–737. Epub 2013 Jul 18.
14. Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med. 2014;370(17):1576–8.
15. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–70.
16. Centers for Disease Control and Prevention. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005–2011. 2013;10;62(18):357–61.
17. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.
18. Centers for Disease Control and Prevention. Locations and reasons for initial testing for hepatitis C infection - chronic hepatitis cohort study, United States, 2006–2010. 2013;62(32):645–8.
19. Beckwith CG, Kurth A, Bazerman L, Solomon L, Patry E, Rich JD, Kuo I. HCV Testing in correctional facilities: a routine testing recommendation is urgently needed. Am J Public Health. Forthcoming 2014.
20. Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14:74.
21. Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.
22. Martin NK, Hickman MN, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8).
23. Fusfeld L, Aggarwal J, Dougher C, Vera-Lonch M, Bubb S, Donepudi M, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13:234.
24. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24(12):753–62.
25. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103(10):e81–8.
26. Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, et al. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58(5):890–7.
27. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207(Suppl 1):S19–25.
28. Moorman AC, Gordon SC, Rupp LB, Spradling PR, Tashale EH, Lu M, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56(1):40–50.
29. Cachay ER, Hill L, Wyles DL, Torriani FJ, Ballard C, Colwell B, et al. The hepatitis C cascade of care among HIV infected patients following diagnosis of HCV infection [Abstract 672]. Top Antivir Med. 2014;22(e-1):335.
30. Yehia BR, Schranz AJ, Umscheid CA, Lo Re III V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systemic review and meta-analysis. PLoS ONE. 2014;9(7):e101554–e101554.
31. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20(11):745–60.
32. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126–33.
33. Ditah IC, Ngwa T, Ditah CM, Ewelukwa O, Kamath PS. Bridging the gap between HCV screening and access to necessary care: National Health and Nutrition Examination Survey HCV follow-up, 2001–2010 [Su1027]. Gastroenterology. 2014;146(5 Suppl 1):S-966.
34. Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLOS One. 2014;9(5):e97317.
35. Trooskin SB, Hadler J, St Louis T, Navarro VJ. Geospatial analysis of hepatitis C in Connecticut: a novel application of a public health tool. Public Health. 2005;119(11):1042–7.
36. Astell-Burt T, Flowerdew R, Boyle P, Dillon J. Is travel-time to a specialist center a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Soc Sci Med. 2012;75(1):240–7.
37. Astell-Burt T, Flowerdew R, Boyle PJ, Dillon JF. Does geographic access to primary healthcare influence the detection of hepatitis C? Soc Sci Med. 2011;72(9):1472–81.
38. Monnet E, Ramée C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med. 2008;66(5):1046–56.
39. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53(3):737–45.
40. Searson G, Engelson SE, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int. 2014;34(5):668–71.
41. Nunn A, Yolken A, Cutler B, Trooskin S, Wilson P, Little S, et al. Geography Should Not Be Destiny: Focusing HIV/AIDS Implementation Research and Programs on Microepidemics in US Neighborhoods. Am J Public Health. 2014;104(5):775–80.
42. Meyers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios AR, Sweeney MM, et al. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. J Acquir Immune Defic Syndr. 2012;61(1):23–31.
43. Tohme RA, Xing J, Liao Y, Holmberg SD. Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009–2010. Am J Public Health. 2013;103(1):112–9.
44. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis c testing and care. Hepatology. 2014. doi:10.1002/hep.27584.
45. Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, et al. Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer. 2008;113(8):1999–2010.
46. Vargas RB, Cunningham WE. Evolving trends in medical care-coordination for patients with HIV and AIDS. Curr HIV/AIDS Rep. 2006;3(4):149–53.
47. Ferrante JM, Winston DG, Chen P-H, de la Torre AN. Family physicians’ knowledge and screening of chronic hepatitis and liver cancer. Fam Med. 2008;40(5):345–51.
48. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377–83.
49. Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: Role of race and ethnicity. World J Gastroenterol. 2007;13(7):1074–10.
50. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.
51. Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, et al. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model – Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393–8.
52. Stockman LA, Guilfoyle SM, Benoit AL, Vergeront JM, Davis JP. Rapid hepatitis C testing among persons at increased risk for infection – Wisconsin, 2012–2013. MMWR Morb Motal Wkly Rep. 2014;63(14):309–311.